173 related articles for article (PubMed ID: 20832894)
1. A multicenter phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer.
Rhee CK; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim CH; Shim BY; Kim HK; Sun DS; Kim KH
Lung Cancer; 2011 Apr; 72(1):64-7. PubMed ID: 20832894
[TBL] [Abstract][Full Text] [Related]
2. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer.
Kim SJ; Kim JS; Kim SC; Kim YK; Kim YK; Kang JY; Yoon HK; Song JS; Lee SH; Moon HS; Kim JW; Kim KH; Kim CH; Shim BY; Kim HK
Lung Cancer; 2010 Jun; 68(3):446-9. PubMed ID: 19683359
[TBL] [Abstract][Full Text] [Related]
3. A multicenter phase II study of belotecan, a new camptothecin analogue, in elderly patients with previously untreated, extensive-stage small cell lung cancer.
Yeo CD; Lee SH; Kim JS; Kim SJ; Kim SC; Kim YK; Kang HH; Yoon HK; Song JS; Moon HS; Kim JW; Kim KH; Shim BY; Kim CH
Cancer Chemother Pharmacol; 2013 Oct; 72(4):809-14. PubMed ID: 23918044
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase 2 study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Lee DH; Kim SW; Suh C; Lee JS; Ahn JS; Ahn MJ; Park K; Na II; Lee JC; Ryoo BY; Yang SH
Cancer; 2010 Jan; 116(1):132-6. PubMed ID: 19904804
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacologic study of belotecan in combination with cisplatin in patients with previously untreated extensive-stage disease small cell lung cancer.
Lee DH; Kim SW; Bae KS; Hong JS; Suh C; Kang YK; Lee JS
Clin Cancer Res; 2007 Oct; 13(20):6182-6. PubMed ID: 17947485
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and toxicity of belotecan for relapsed or refractory small cell lung cancer patients.
Kim GM; Kim YS; Ae Kang Y; Jeong JH; Kim SM; Hong YK; Sung JH; Lim ST; Kim JH; Kim SK; Cho BC
J Thorac Oncol; 2012 Apr; 7(4):731-6. PubMed ID: 22425922
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
[TBL] [Abstract][Full Text] [Related]
8. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial.
Jeong J; Cho BC; Sohn JH; Choi HJ; Kim SH; Lee YJ; Jung MK; Shin SJ; Park MS; Kim SK; Chang J; Kim JH
Lung Cancer; 2010 Oct; 70(1):77-81. PubMed ID: 20138389
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.
Ettinger DS; Jotte R; Lorigan P; Gupta V; Garbo L; Alemany C; Conkling P; Spigel DR; Dudek AZ; Shah C; Salgia R; McNally R; Renschler MF; Oliver JW
J Clin Oncol; 2010 May; 28(15):2598-603. PubMed ID: 20385980
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
11. Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study.
Lee DH; Kim SW; Suh C; Lee JS; Lee JH; Lee SJ; Ryoo BY; Park K; Kim JS; Heo DS; Kim NK
Ann Oncol; 2008 Jan; 19(1):123-7. PubMed ID: 17823384
[TBL] [Abstract][Full Text] [Related]
12. Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs.
Park YH; Chung CU; Park BM; Park MR; Park DI; Moon JY; Park HS; Kim JH; Jung SS; Kim JO; Kim SY; Lee JE
Can Respir J; 2016; 2016():3576201. PubMed ID: 28018128
[No Abstract] [Full Text] [Related]
13. Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer.
Lim S; Cho BC; Jung JY; Kim GM; Kim SH; Kim HR; Kim HS; Lim SM; Park JS; Lee JH; Kim D; Kim EY; Park MS; Kim YS; Kim SK; Chang J; Kim JH
Lung Cancer; 2013 Jun; 80(3):313-8. PubMed ID: 23510628
[TBL] [Abstract][Full Text] [Related]
14. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
Punt CJ; de Jonge MJ; Monfardini S; Daugaard G; Fiedler W; Baron B; Lacombe D; Fumoleau P;
Eur J Cancer; 2004 Jun; 40(9):1332-4. PubMed ID: 15177492
[TBL] [Abstract][Full Text] [Related]
15. A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
Baka S; Ranson M; Lorigan P; Danson S; Linton K; Hoogendam I; Mettinger K; Thatcher N
Eur J Cancer; 2005 Jul; 41(11):1547-50. PubMed ID: 16026691
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
Kang JH; Lee KH; Kim DW; Kim SW; Kim HR; Kim JH; Choi JH; An HJ; Kim JS; Jang JS; Kim BS; Kim HT
Br J Cancer; 2021 Feb; 124(4):713-720. PubMed ID: 33191408
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of uterine cervix.
Hwang JH; Lim MC; Seo SS; Park SY; Kang S
Jpn J Clin Oncol; 2011 May; 41(5):624-9. PubMed ID: 21355002
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Shimizu K; Imai H; Utsugi M; Iwasaki Y; Iijima H; Tsurumaki H; Yoshii A; Fueki N; Hisada T; Ishizuka T; Saito R; Mori M
Lung Cancer; 2010 Jul; 69(1):99-104. PubMed ID: 19853960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]